Nuclear lamins are involved in many cellular functions due to their ability to bind numerous partners including chromatin and transcription factors, and affect their properties. Dunnigan type familial partial lipodystrophy (FPLD2; OMIM#151660) is caused in most cases by the A-type lamin R482W mutation. We report here that the R482W mutation affects the regulatory activity of sterol response element binding protein 1 (SREBP1), a transcription factor that regulates hundreds of genes involved in lipid metabolism and adipocyte differentiation. Using in situ proximity ligation assays (PLA), reporter assays and biochemical and transcriptomic approaches, we show that interactions of SREBP1 with lamin A and lamin C occur at the nuclear periphery and in the nucleoplasm. These interactions involve the Ig-fold of A-type lamins and are favored upon SREBP1 binding to its DNA target sequences. We show that SREBP1, LMNA and sterol response DNA elements form ternary complexes in vitro. In addition, overexpression of A-type lamins reduces transcriptional activity of SREBP1. In contrast, both overexpression of LMNA R482W in primary human preadipocytes and endogenous expression of A-type lamins R482W in FPLD2 patient fibroblasts, reduce A-type lamins-SREBP1 in situ interactions and upregulate a large number of SREBP1 target genes. As this LMNA mutant was previously shown to inhibit adipogenic differentiation, we propose that deregulation of SREBP1 by mutated A-type lamins constitutes one underlying mechanism of the physiopathology of FPLD2. Our data suggest that SREBP1 targeting molecules could be considered in a therapeutic context.
Introduction
A-type lamins include lamins A (LMNA) and C (LMNC) that arise from alternative RNA splicing from the LMNA gene. These intermediate filament proteins are expressed in most differentiated cells where they locate both at the nuclear envelope, as a constituent of the nuclear lamina together with B-type lamins, and in the nucleoplasm (1). Lamins have a central α-helical rod domain flanked by a small N-terminal head and a large C-terminal tail which contains a globular immunoglobulin (Ig)-like domain. LMNA is generated by processing of the precursor prelamin A ( pre-LMNA) which after farnesylation is modified by proteolysis of its last 18 amino acids (2) .
Numerous mutations scattered throughout the LMNA protein give rise to diseases commonly called laminopathies that affect muscle, cardiac, adipose, cartilage and bone tissues or lead to premature aging syndromes (3) . Dunnigan-type familial partial lipodstrophy (FPLD2; OMIM#151660) is an autosomal-dominantly inherited puberty-onset laminopathy, associating fat loss in the limbs and fat hypertrophy and fibrosis in the cervicofacial region (4) . Subsequent metabolic alterations lead to severe hypertriglyceridemia, insulin-resistant diabetes and early atherosclerosis.
The underlying physiopathological mechanisms of laminopathies imply a modification of their function notably in gene expression regulation via a modification in their capacity to bind either DNA, histones and/or various transcriptional regulators (5) (6) (7) (8) (9) . For instance, in the context of premature aging, unprocessed LMNA or a LMNA mutant named progerin were reported to have distinct binding capacities to histone modifiers as SIRT1, SUV39H1 and MOF (7, 10, 11) . In the context of FPLD2, which is caused in most cases by the heterozygous substitution p.R482W in the LMNA gene (12) (13) (14) , LMNA binding to the fragile X protein family member FRX1P was reported to be weakened, with implications on adipogenesis (15) ; however, to what extent is A-type lamin binding to the transcription factor sterol response element binding protein 1 (SREBP1) affected by FPLD2 A-type lamin mutations remains unclear. Indeed, in vitro pull-down assays using recombinant proteins and microscopy analyses of FPLD2 patient fibroblasts have reported either an increase, a decrease or no change in the ability of FPLD2-causing LMNA mutants, compared with wild-type (wt) LMNA, to bind SREBP1 (16) (17) (18) . SREBP1 exists in two major isoforms (1a, 1c) and as isoform 1ac, which differ only within their N-termini, and are expressed at different ratios in a tissue-dependent manner (19) (20) (21) . While SREBP1a is constitutively expressed at low ratios in most tissues, SREBP1c expression is stimulated by environmental factors (22) . SREBP1 proteins are synthesized as precursors that are retained in the endoplasmic reticulum membrane via insulin-induced gene protein binding to SREBP-cleavage-activating-protein (SCAP)-bound SREBP. Upon high insulin or decreased sterol levels, SCAP-SREBP dissociates from the Insig protein and relocates to the Golgi where SREBP is cleaved by two site proteases, giving rise to mature SREBP1 (22) . After translocation to the nucleus, mature SREBP1 dimers bind to specific DNA sequences called sterol regulatory elements (SREs) and activate transcription of several hundreds of target genes. Genome-wide and microarray analysis revealed that in liver and muscle cells, SREBP1 proteins regulate expression of genes involved in the metabolism of lipids, carbohydrates, amino acids, as well as genes implicated in other signaling pathways (23, 24) . In mice models, forced overexpression of SREBP1a or SREBP1c in adipose tissue leads to adipocyte hypertrophy or lipodystrophy, respectively (25, 26) , indicating that fine tuning of adipogenesis requires appropriate expression of SREBP1 factors. Moreover, in humans, deregulation of SREBP1 is observed in conditions associated with metabolic syndrome (obesity, insulin resistance) and aberrantly increases lipogenesis as in cancers highlighting the therapeutic potential of targeting SREBP proteins (27, 28) .
Since (i) wt A-type lamins interact with SREBP1, (ii) SREBP1 plays a key role in lipid metabolism and in adipocyte differentiation (29, 30) and (iii) FPLD2 caused by A-type lamin mutations affects adipose tissue, we rationalized that deregulation of SREBP1 activity may be involved in the pathology of FPLD2. In this study, using reporter cell lines, primary human adipocyte progenitors expressing wt and mutant LMNA, and FPLD2 patient cells, we show that the FPLD2-causing R482W mutation impairs the transcriptional activity of SREBP1.
Results

A-type lamin overexpression downregulates transcription from an SREBP1-responsive promoter
We first determined, using a luciferase reporter assay, whether A-type lamins regulate SREBP1 activity. HeLa cells were cotransfected with plasmids encoding HA-tagged SREBP1ac or SREBP1c isoforms, FLAG-tagged pre-LMNA wt, a pre-LMNA L647R mutant (unable to be processed into mature lamin A due to mutation in its proteolytic cleavage site), a pre-LMNA R482W mutant (responsible for FPLD2), LMNA or LMNC (lamin C), firefly luciferase and renilla luciferase (Supplementary Material, Fig. S1 ). In this assay, luciferase synthesis depends on SREBP1 binding to wt SRE sequences inserted in the luciferase promoter. Both HA-SREBP1ac and HA-SREBP1c induce an increase in luciferase activity (Fig. 1A) . However, HA-SREBP1ac-induced luciferase activity decreases after expression of FLAG-pre-LMNA in a dose-dependent manner (Fig. 1A) . Similarly, overexpression of a FLAG-pre-LMNA(L647R), FLAG-pre-LMNA(R482W), mature FLAG-LMNA or FLAG-LMNC also elicits a significant reduction in luciferase activity (Fig. 1A) . As expected, exogenous FLAG-pre-LMNA (wt or R482W) was processed into mature LMNA in contrast to FLAG-pre-LMNA(L647R) (Fig. 1B and Supplementary Material, Fig. S2A ). In comparison, overexpression of emerin does not affect luciferase activity (Fig. 1A) . Thus, overexpression of nuclear lamins, irrespective of their processing, impairs the transcriptional activity of SREBP1.
As nuclear A-type lamins have been shown to bind SREBP1 (17,18), we next asked whether SREBP1-dependent transcription was affected by binding to LMNA. We co-expressed in HeLa cells HA-SREBP1ac and either SRE-luciferase or FLAG-LMNA. As expected, FLAG-LMNA is enriched at the nuclear envelope, HASREBP1ac (mature full-length SREBP1) is in the nucleoplasm, while luciferase is detected both in the nucleoplasm and cytoplasm, with various intensities within the cell population (Fig. 1C ). Cells were also processed simultaneously by immunofluorescence to detect the luciferase protein and by proximity ligation assay (PLA) to reveal in situ protein interactions between HA-SREBP1 and FLAG-LMNA (Fig. 1D) . A negative control experiment reveals no HA-SREBP1-FLAG-LMNA complexes in the absence of ectopic lamins, while luciferase is expressed (Fig. 1D , upper panels). In contrast, co-expression of FLAG-LMNA promotes the formation of complexes with SREBP1, detected by PLA predominantly at the nuclear periphery (Fig. 1D , lower panels). We observed cells with high luciferase expression displaying rare PLA signals (arrowheads, Fig. 1D ), and inversely cells with weak luciferase expression displaying numerous PLA signals (arrows, Fig. 1D ). These results are compatible with a model where LMNA-SREBP1 complexes would reduce SREBP1 transcriptional activity in a manner dependent on SRE DNA sequences. Material, Fig. S2A ), but not in SREBP1 mRNA levels (Supplementary Material, Fig. S2B ), suggesting that high levels of A-type lamins lead to enhanced HA-SREBP1 protein stability. Although, as expected, immunofluorescence reveals A-type lamins both at the nuclear envelope and in the nucleoplasm, FLAG-LMNC is also frequently (47% of the transfected cells) detected within intranuclear ring-like structures ( Fig. 2A, upper panels) . In parallel, cells were processed by PLA to reveal in situ protein interactions between FLAG-tagged lamins and HA-SREBP1 and then by immunofluorescence to detect FLAG positive cells ( Fig. 2A,  lower panels) . While PLA signals are absent in untransfected cells ( Fig. 2A, arrowhead in the lower panel) , nearly all FLAG positive cells (94-97%) show PLA signals, albeit with various amounts per nucleus. Our quantitative estimation reveals that all ectopic A-type lamins studied here are able to efficiently interact in situ with HA-SREBP1 (Fig. 2B) , with FLAG-LMNC expressing cells showing the higher amount of PLA signals per nucleus (P < 0.01, Kruskal and Wallis test). The detection of PLA signals close to the nuclear periphery (<0.8 µm) occurred with a similar frequency upon overexpression of FLAG-pre-LMNA wt, L647R, or R482W, or FLAG-LMNA, but is significantly reduced upon overexpression of FLAG-LMNC (P < 0.001). Altogether, these results highlight the capacity of SREBP1 to interact with all A-type lamin isoforms, both at the nuclear envelope and in the nucleoplasm.
SREBP1, LMNA and SRE DNA elements form ternary complexes
We have previously shown that the DNA-binding domain of SREBP1 lies within its lamin binding domain (17) . Thus, LMNA interaction with SREBP1 may impair SREBP1 binding to DNA target sequences and subsequently reduce the transcriptional activity of SREBP1. This reasoning is consistent with the reduced luciferase activity observed above upon overexpression of LMNA. To determine whether SREBP1 can interact simultaneously with LMNA and its target DNA elements, we first carried out a Human Molecular Genetics, 2015, Vol. 24, No. 7 | 2099 chromatin immunoprecipitation (ChIP) of FLAG-LMNA from HeLa cells expressing (5X)SRE-luciferase and either HA-SREBP1, FLAG-pre-LMNA or both (Fig. 3A) , and assessed enrichment in SRE sequences. Figure 3B clearly shows SRE DNA enrichment in LMNA ChIPs from cells co-expressing FLAG-LMNA and HA-SREBP1 compared with cells expressing FLAG-LMNA or HA-SREBP1 alone. Second, pull-down of a GST-tagged C-terminal fragment of LMNA (residues 389-646) able to co-precipitate a His-SREBP1 peptide (residues 227-487 of SREBP1a; 17) weakly co-precipitates mature recombinant HA-SREBP1c; however, co-precipitation is markedly more efficient in the presence of (5X)SRE DNA (Fig. 3C ). We conclude that interaction of LMNA with SREBP1 is favored upon SREBP1 binding to free SRE DNA sequences, suggesting the existence of LMNA-SREBP1-DNA complexes.
To further establish the role of DNA in the LMNA-SREBP1 interaction, we deleted amino acids 304-312 of SREBP1 (HA-SREBP1[Δ304-312]; Supplementary Material, Fig. S1 ) to abrogate the DNA interacting domain (31) , and assessed its ability to interact with FLAG-LMNA in cells. While both wt and mutant HA-SREBP1 localize in the nucleoplasm as expected (Fig. 4A ), HA-SREBP1-FLAG-LMNA interactions are detected by PLA predominantly in cells co-expressing wt HA-SREBP1 but not HA-SREBP1(Δ304-312) (Fig. 4B ). We find that both the proportion of PLA-positive cells showing interactions (Fig. 4C) , and the number of PLA signals per nucleus (Fig. 4D ), are lower in cells expressing HA-SREBP1(Δ304-312) relative to HA-SREBP1 (P < 0.001, Kruskal and Wallis test). This was not due to differential spatial enrichment of wt or mutant HA-SREBP1, as with both proteins the same proportion (∼25%) of SREBP1-LMNA complexes are detected close to (<0.8 µm) the nuclear periphery (data not shown). In addition, the reduction in SREBP1-LMNA interactions after deletion of the DNA-binding domain of SREBP1 cannot be explained by a decreased expression of HA-SREBP1 or FLAG-LMNA in these experiments: overexpression of LMNA coincides with a ∼2-fold increase in HA-SREBP1c wt or mutant protein level (Supplementary Material, Fig. S2C ). Of note, a point mutation in the DNA-binding domain of SREBP1 (Y311R in SREBP1c) did not affect SREBP1-LMNA interactions (data not shown). These results indicate that the DNA-binding domain of SREBP1 is involved in SREBP1-LMNA interactions; this is consistent with a role of DNA in mediating or maintaining these interactions.
The Ig fold of LMNA is important for interaction of LMNA with SREBP1
We have previously shown that the C-terminal domain of LMNA involved in SREBP1 binding is common to all A-type lamins (17) . We now asked whether the Ig fold of LMNA, which is shared by the pre-LMNA, LMNA and LMNC isoforms, contributes to SREBP1 binding. We find that LMNA deleted of the Ig fold (LMNA[Δ429-547]; Supplementary Material, Fig. S1 ) localizes both at the nuclear envelope and in the nucleoplasm, but in contrast to wt LMNA, it frequently accumulates within nuclear foci (Fig. 5A ). LMNA(Δ429-547) significantly reduces interactions with SREBP1 detected by PLA (Fig. 5B-D) and again, this was not due to a reduction of HA-SREBP1 or GFP-LMNA protein levels (Supplementary Material, Fig. S2D ). Thus, the Ig fold of LMNA is implicated in SREBP1-LMNA interactions directly and/or indirectly due to the modification of the lamina network.
Overexpression of the LMNA p.R482W mutation causing FPLD2 reduces LMNA-SREBP1 interactions and upregulates SREBP1 target genes in preadipocytes
Since R482 is located within the Ig fold of LMNA which is implicated in SREBP1 binding (see above), and since overexpression of LMNA p.R482W impairs adipogenic differentiation of human adipose stem cells (ASCs) in vitro (15), we asked whether, in an adipogenic context, the LMNA p.R482W mutation would alter LMNA binding to SREBP1 and alter expression of SREBP1 target genes. We established cultures of primary ASCs expressing wt GFP-LMNA or a GFP-LMNA(R482W) mutant in a doxycyclineinducible manner (15) . Immunological analyses confirm enrichment of GFP-LMNA and the GFP-LMNA(R482W) at the nuclear envelope ( Fig. 6A ) and expression levels comparable with endogenous lamins A and C (Fig. 6B) . Cells expressing LMNA R482W show nuclear dysmorphies typical of laminopathies ( Fig. 6A and C) (32, 33) . In contrast to HeLa cells, ASCs, which are pre-committed to adipogenesis, express significant levels of mature SREBP1 (Fig. 6B) ; this enables the determination of interactions of endogenous SREBP1 with wt or mutant GFP-LMNA by PLA in cells. Indeed, we detect interactions (Fig. 6C) We next determined whether expression of SREBP1 target genes was affected by the LMNA mutation. As part of a separate study, we have generated by deep RNA-sequencing (RNA-seq) transcriptomic datasets for ASCs expressing GFP-LMNA, GFP-LMNA(R482) or GFP alone (A.R. Oldenburg et al., submitted for publication). In an assessment of mRNA levels for 57 annotated SREBP1-responsive genes identified in HepG2 hepatocarcinoma cells (23), we find that in undifferentiated ASCs, 27 of these genes are upregulated with a mean of 1.40 ± 0.46-fold in cells expressing GFP-LMNA(R482W) relative to wt GFP-LMNA ( Fig. 6E and F; P < 10 −4 ; one-sided t-test). Moreover, after 9 days of adipogenic differentiation 46/57 genes are upregulated (1.52 ± 0.44-fold; P < 10 −4 ) in cells expressing mutant versus wt LMNA (Fig. 6E and F) . Human
Interestingly, we also find that overexpression of wt GFP-LMNA in ASCs causes a moderate but significant overall down-regulation of these SREBP1 target genes ( Fig. 6F , P < 10 −4, one-sided t-test;
see Fig. 6E for expression patterns of the individual genes); this is consistent with our earlier findings that overexpression of LMNA elicits down-regulation of transcription from an SREBP1-responsive promoter (see Fig. 1A ). Altogether, these data indicate that (i) overexpression of LMNA downregulates SREBP1 target genes, and (ii) induction of expression of LMNA R482W in undifferentiated and differentiated adipocyte progenitors elicits an upregulation of SREBP1 target genes. This transcriptional effect correlates with a lower incidence of LMNA-SREBP1 interaction in these cells.
The LMNA R482W mutation reduces LMNA-SREBP1 in situ interactions and elicits upregulation of SREBP1 target genes in FPLD2 patient fibroblasts
To alleviate potential limitations on SREBP1 target gene expression due to the overexpression of lamins, we assessed the effect of endogenous levels of LMNA R482W on lamin A/C-SREBP1 interactions and SREBP1 target gene expression. We used fibroblasts from FPLD2 patients with a heterozygous LMNA mutation leading to a p.R482W substitution. Lamin A/C is enriched at the nuclear envelope in control and FPLD2 patient fibroblasts (Fig. 7A) . SREBP1 is found both in the cytoplasm, likely corresponding to an immature pool, and in the nucleoplasm as expected for mature nuclear SREBP1, with similar distribution and levels in control and patient cells ( Fig. 7A and B) . We find that PLA reveals interactions between endogenous SREBP1 and endogenous lamin A/C throughout the nuclear compartment in all nuclei of controls and FPLD2 fibroblasts (Fig. 7C ) with however ∼50% fewer signals per nucleus in FPLD2 versus control cells (Fig. 7D ). In both cell types the nuclear distribution of PLA signals is similar, with ∼20-25% of signals localizing at the nuclear periphery (<0.9 µm from the nuclear border defined by DAPI staining) both in early and late passage cells ( passages 7-12 and 18-19; Supplementary Material, Fig. S3 ). This decrease in total PLA signals per nucleus (Fig. 7D) was not due to variations in expression of either protein (Fig. 7B) . Second, RNA-seq data sets of the transcriptome of fibroblasts from two controls and two FLPD2 patients (distinct from those examined above; A.R. Oldenburg et al., submitted for publication) were assessed for the 59 SREBP1 target genes examined above. We find that 46 genes out of the 59 SREBP1 target genes are upregulated (Fig. 7E ) by a mean of 2.15 ± 0.22-fold (P < 10 −4 ; Fig. 7F ) in fibroblasts from FPLD2 patients relative to control fibroblasts. We conclude that the LMNA R482W mutation causing FPLD2 reduces the frequency of endogenous lamin A/C-SREBP1 interactions and elicits upregulation of SREBP1 target genes in patient fibroblasts. This suggests that expression of the LMNA(R482W) mutant results in greater transcriptional activity of SREBP1.
Discussion
Role of DNA in recognition of SREBP1 by A-type lamins
We have used complementary approaches to show that LMNA preferentially interacts with SREBP1 bound to DNA rather than free SREBP1. Interestingly, co-crystal structure of SREBP1 peptide dimers bound to DNA via their basic region reveals that SREBP1, as other Helix-loop-helix proteins, recognizes DNA through an induced fit process involving a DNA sequence-directed folding transition (31, 34) . Side chain-base and side chain-backbone interactions likely stabilize the alpha-helical conformation of the basic regions of SREBP1. From our data, we speculate that three-dimensional structural changes of SREBP1 dimers that occur upon binding to SRE DNA elements induce and/or strengthen interaction with A-type lamins. In addition, in situ co-location of A-type lamins-SREBP1 complexes at the nuclear periphery and in the nucleoplasm suggests that distinct pools of A-type lamin polymers, either within the lamina at the nuclear 
Mechanisms of SREBP1 transcriptional activity inhibition by A-type lamins
In response to overexpression of LMNA, transcriptional activity of SREBP1 decreases despite the detection of increasing levels of SREBP1, indicating that the additional pool of SREBP1 proteins is mostly inactive. This result is consistent with the transcriptiondependent proteosomal degradation reported for SREBP1 (36) . Several hypotheses may be proposed to account for the reduction of SREBP1 function in response to overexpression of LMNA. A first possibility is that A-type lamins bind and sequester SREBP1 molecules away from their DNA target sequences; this model however is not supported by the preference of LMNA for DNAbound SREBP1 rather than free SREBP1 (this paper). (ii) A-type lamins may associate with and displace DNA-bound SREBP1 to a transcriptionally inactive nuclear compartment such as the nuclear envelope or lamina-associated domains (37) (38) (39) (40) (7) and the expression of ubiquitin ligases (46) (47) (48) ; these factors are critically involved in SREBP1 post-translational modifications which in turn intervene in the regulation of the stability and activity of SREBP1 (49-51).
The FPLD2 LMNA p.R482W substitution deregulates SREBP1 function
In HeLa cells, we observed that LMNA wt and LMNA R482W have a similar negative impact on the SRE-dependent transcriptional activity of SREBP1, consistent wih the fact they have a similar capacity to form in situ complexes with SREBP1 in this cellular context. In contrast, both in human fibroblasts and adipose progenitor cells, we show that expression of LMNA R482W specifically elicits up-regulation of numerous SREBP1 target genes, in correlation with a marked decrease (45-65%) in the number of LMNA-SREBP1 in situ interactions. Accordingly, the R482W substitution associated with a 45% decrease in LMNA binding to SREBP1 in vitro (18) . These data suggest that residue R482 in the Ig-like fold of LMNA (52) is part of the SREBP1 interaction domain. Interestingly, the fact that a specific impact of LMNA R482W on SREBP1 was observed in only two of the three cellular models used here, suggests that the cell-type specificity and/or the variability in mutant/wt LMNA ratios would contribute to the regulation of SREBP1 function. In light of our findings, we propose a model wherein A-type lamins negatively regulate SREBP1 function by binding to SREBP1 itself, whereas loss of function of R482W A-type lamins in their ability to bind SREBP1 leads to derepression of subsets of SREBP1 target genes. However, for specific genes whose transcription is inhibited by SREBP1 (see for e.g. 53,54), it is possible that A-type lamins co-operate with SREBP1 to silence such genes, and that the reduced ability of the mutant A-type lamins to interact with SREBP1 impairs their silencing. On one hand, FPLD2 patient fibroblasts prematurely enter senescence (55) and on the other hand, increased SREBP1 activity (due to ectopic mature SREBP1 overexpression) induces increased lipogenesis and triggers senescence in normal human fibroblasts (56). Thus, the higher transcriptional activity of SREBP1 reported in our study in FPLD2 patient fibroblasts might also contribute to their early senescence. SREBP1 is considered as a master regulator of adipogenesis (29, 30) . However, adipose-specific overexpression of either the constitutionally active isoform SREBP1a or of SREBP1c results in strikingly different phenotypes in mice, i.e. hypertrophy of fully differentiated white adipocytes with enlarged interscapular brown fat pads, or loss of peripheral white fat with hypertrophic immature interscapular brown fat, respectively (25, 26) . Therefore, highly regulated SREBP1 functions are needed for physiological adipocyte differentiation and/or maturation, which differ in the different adipose tissue depots. It is thus possible that altered expression of SREBP1 target genes could lead to lipodystrophy in humans with different consequenses on the physiologically different adipose tissues. In accordance, our present results show that mRNA expression of several genes known to be involved in preadipocyte clonal expansion (cell cycle regulators), adipocyte differentiation (PPARG) and mature adipocyte functions (lipogenesis and lipid metabolism) are dysregulated in cells expressing LMNA R482W. In addition, in FPLD2, body distribution of adipose tissue is altered, with loss of peripheral subcutaneous fat and accumulation of dystrophic brown-like fat in cervicofacial areas (57) ; this is reminiscent of what has been described in mice overexpressing SREBP1c in adipose tissue. Therefore, the higher SREBP1 activity (this paper) together with the adipocyte differentiation deficiency we observed in ASCs overexpressing LMNA R482W (15) , suggest that SREBP1 deregulation might be part of the underlying physiopathological mechanisms leading to the lipodystrophic phenotype of FPLD2.
Since SREBP1 deregulation is observed in diverse pathological contexts, including metabolic syndromes, cancers, neurodegenerative disease and hepatitis C viral infection, use of molecules able to modulate the expression/activity of SREBP1 is presently considered as a pertinent therapeutic approach (27, 28) . Of note, different molecules or bioactive peptides which target the Insig or SCAP molecules and consequently block SREBP1 processing were shown to reduce SREBP1 activity in mice (58, 59) . Alternatively, nutritional control or drugs modulating specific signaling pathways might also be considered to modulate SREBP1 expression/function with a specific emphasis on the activation of AMPK pathway (28) . The impact of such molecules may conceivably be evaluated for therapeutic treatments of some laminopathies as FPLD2.
Materials and Methods
Patients and cells
All individuals gave their informed consent for these studies, which were approved by an institutional review board. Patients FPLD2-1 (LH, 51 years), FPLD2-2 (KL, 43 years) and FPLD2-3 (LN, 20 years) carried a p.R482W heterozygous substitution in LMNA (14,33 and C.V., unpublished observations). Subcutaneous fibroblasts from the FPLD2 patients (obtained by skin biopsy) and from two control women (CTL-1 and CTL-2; ND 33 years and HR 43 years, respectively) without known disease and who underwent cosmetic surgery, were collected cultured in Dulbecco's Modified Eagle Medium (Gibco) containing 10% fetal calf serum (FCS) for a maximum of 19 passages.
Fibroblasts used for RNA-seq were human primary dermal fibroblasts from Lonza (CC-2511; LDFs) and from the Norwegian Stem Cell Center (AD04DFs) as described (60) . These fibroblasts were cultured in DMEM/F12 containing 10% FCS and 2 ng/ml basic fibroblast growth factor. Cells were collected at passages 5-7 for RNA isolation. AD04DFs were obtained with Norwegian Ethics Committee Approval REK2617A. FPLD2 fibroblasts used for RNA-seq were from two other patients with the heterozygous LMNA p.R482W mutation. ASCs were obtained and cultured as described earlier (15) with Norwegian Ethics Committee Approval REK06387A.
Plasmids
Plasmids encoding hemagglutinin (HA) fusions of SREBP1ac and SREBP1c were generated by PCR amplification of sequences encoding amino acids 1-517 and 1-463, respectively, using pBluescriptR-SREBP1 (clone IRATp970G1266D; imaGenes) as template. The amplified DNA was ligated into the EcoRI and XbaI sites of pcDNA3-3HA (a gift from Dr Sabrina Pichon). pCDNA-HASREBP1c deleted for the basic domain (Δ304-312) was constructed by site-directed mutagenesis using the Metamorph mutagenesis kit (SystemBio). pSVK3 plasmids encoding FLAG fusions of prelamin A (residues 1-664), lamin A (residues 1-646), lamin C Human Molecular Genetics, 2015, Vol. 24, No. 7 | 2105 (residues 1-572) and emerin and pEGFP vectors encoding wt lamin A or lamin A deleted of the Ig fold (Δ429-547) were produced as described (15, 17, 32, 61) . To generate a pGL4.23-SRE-firefly luciferase vector, oligonucleotides corresponding to 5× repeats of the wt SRE DNA sequence issued from the LDLR promoter (5′-AAAATCACCCCACTGCAAACTCCTCCCCCTGC-3′) or mutated SRE DNA sequences (5′-AAAAGAACCCCTATGCAAA CTCCTCCCCCTGC-3′) were synthesized and purified (Sigma), annealed and cloned into PGL4.23[luc2/minP] using XhoI and HindIII cloning sites. The pRL-SV40-renilla luciferase vector was used as a control vector to normalize luciferase reporter gene assays (Promega).
Transfection
HeLa cells were obtained from American Type Culture Collection and cultured in Minimum Essential Medium containing Glutamax (Gibco), 1% non-essential amino acids and 10% fetal bovine serum. HeLa cells were transfected using Fugen 6, XtremeGene 9 (Roche) or lipofectamine (Invitrogen). After 24-48 h, cells were processed for assays as indicated in the text. Human ASCs transduced with lentiviral vectors to inducibly express GFP-LMNA or GFP-LMNA(R482W) were as previously described (15) .
Immunoblotting
Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes. Membranes were blocked for 1.5 h in TBS (10 m Tris pH 8.0, 150 m NaCl, 0.05% Tween-20) containing 5% dry milk, incubated with primary antibodies for 1 h in TBS/ 1% milk, washed four times and incubated with HRP-conjugated secondary antibodies. After four washes in TBS, proteins were detected by enhanced chemiluminescence. Signals were quantified by densitometry using ImageJ (NIH). Primary antibodies used were rabbit anti-SREBP1 (K10; Santa Cruz Biotechnology; 1:350 dilution), mouse anti-FLAG (M2; Sigma, 1:650), mouse anti-HA (Sigma, 1:1000), rabbit anti-GAPDH (Sigma, 1:15 000), mouse anti-actin (Sigma, 1:3000) and rabbit anti-lamin A/C (1:5000) (17).
Immunofluorescence
Cells were fixed with 3% paraformaldehyde for 12 min or with methanol for 10 min at −20°C. Primary antibodies were anti-SREBP1 (K10, 1:60), anti-FLAG (M2, 1:300) and anti-HA (1:200) as above, mouse anti-lamin A/C (Novocastra, 1:150), rabbit anti-FLAG (Sigma, 1:150), mouse anti-GFP (Roche, 1 :150) and goat anti-luciferase (Novus Biologicals, 1:250). Secondary antibodies (anti-mouse Cy3, anti-rabbit Cy2, anti-mouse 594, anti-rabbit 594 and anti-goat 488) were from Jackson ImmunoResearch. DNA was stained with Hoechst 33 258 (1 µg/ml).
Proximity ligation assay
Proximity ligation assay was used to detect LMNA-SREBP1 interactions based on proximity (<40 nm) of two secondary antibodies directed against these proteins. First, we used pairs of primary antibodies, namely (rabbit anti-FLAG and mouse anti-HA) or (mouse anti-GFP and rabbit anti-HA) on HeLa cells expressing either FLAG-LMNA and HA-SREBP1, or GFP-LMNA and HA-SREBP1, respectively; (mouse anti-GFP and rabbit anti-SREBP1 K10) on clones of ASCs expressing GFP-LMNA (wt or mutant), and (mouse anti-lamin A/C and rabbit anti-SREBP1 K10) to detect endogenous LMNA-SREBP1 interactions in human fibroblasts. Next, Duolink PLA probe anti-rabbit plus, Duolink PLA probe antimouse minus and Duolink detection reagents orange (detected with a Cy3 filter) were used according to manufacturer's instructions (Olink, Bioscience). In some experiments, an additional step consisting in adding Cy2-conjugated secondary goat antibodies against FLAG or GFP was done to visualize transfected cells. Confocal microscopy image acquisition was performed using a LSM 700 Laser scanning microscope (Zeiss). Quantitative analysis of PLA signals was done on images using a custom image recognition Image J plugin. This relied on a two-step algorithm: first, DNA stain fluorescence was analyzed to compute the nucleus contour by searching the steepest gradient of the radial intensity profile; second, spots corresponding to PLA signals were detected by a watershed algorithm. A final treatment was applied to merge the related spots with rejection of the smallest when relevant (noise rejection). Data were compiled as numbers of recognized pixels as a function of their distance to the closest point of the nuclear periphery. This distance was based on the distance between the nuclear periphery and the nucleus barycenter, thus allowing data comparison from different cells in the population examined. In these analyses, we considered the distance between the periphery and the nucleus barycenter as the maximal distance (100%). The peripheral signals refer to the signals detected within an intranuclear peripheral region limited to 10% of the maximal distance.
Reporter assays
HeLa or HEK293 cells were co-transfected into 96-well plates with four plasmids: (i) pcDNA3-SREBP1 or empty pcDNA3 (CMV promoter), (ii) pGL4.23-(5X)SRE-firefly luciferase, (iii) pSVK3-FLAGlamin or pSVK3 empty (SV40 promoter) and (iv) pRL-SV40 vector (SV40 early enhancer promoter, used as internal control). A total of 24-48 h post-transfection, luciferase expression was assayed using the Dual-Luciferase Reporter Assay system (Promega), and signals were quantified with a microplate luminometer. Reporter data were normalized for inter-well transfection variability by calculating ratios of the Firefly/Renilla signals and an average was calculated from n independent experiments (ratio = Firefly/Renilla). Differences in activity between samples HA-SREBP1 co-expressed with a FLAG-protein ['a'], and HA-SREBP1 expressed alone (i.e co-transfected with a control empty pSVK3 plasmid ['b'] ) were compared by calculating the normalized fold change in activity (Δfold activity) using the following equation: 
GST pull-down
GST and GST-Cter LMNA were produced in bacteria as described (17) . Full-length mature SREBP1c was produced by in vitro translation of pF3A-HA-SREBP1c using the TnT SP6 high yield wheat germ protein expression system (Promega). SRE DNA sequences were amplified by PCR from the pGL4.23-SRE-luciferase plasmid, using primers 5′-TGCAGGTGCCAGAACATTTC-3′ and 5′-TCCATG GTGGCTTTACCAAC-3′. Incubation of GST and GST-Cter LMNA (200 pmoles) with the wheat germ extracts containing HASREBP1c (20 µl) and SRE-DNA (25 pmoles) was done in Tris-EDTA buffer (50 m Tris pH 8, 1 m EDTA, 0.5% Triton X-100, 1 m AEBSF and 150 m NaCl) for 2 h at 4°C. Complexes were recovered with glutathione-sepharose beads (35 µl), and after six washes in Tris-EDTA, complexes were released by addition of 1 volume of 2× Laemmli buffer, separated on 8% SDS-PAGE and analyzed by immunoblotting using anti-HA antibodies.
RT-PCR
Total RNA was extracted using the RNA Easy kit (Qiagen) and onestep RT-PCR was done using the Quantitect SYBR Green RT-PCR assay (Qiagen). Relative mRNA amounts were calculated using the comparative CT method with GAPDH as internal controls. Primers used are shown in Supplementary Material, Table S1 .
RNA-sequencing
Total RNA was isolated using the Ambion TRIzol ® Reagent RNA extraction kit (Life Technologies). A library was prepared (Illumina) and sequenced on an Illumina HiSeq2500. Reads (29.3 × 10 6 )
were aligned using Cufflinks and TopHat (62) using default parameters. RNA-seq data from LDF and AD04 fibroblasts were published earlier and downloaded from NCBI GEO with accession number GSE 54334. RNA-seq experiments were part of a separate study (A.R. Oldenburg et al., submitted for publication).
Statistical analysis
Quantitative results are expressed as means ± SEM. or medians with third and first quartiles. Comparisons between samples were performed with the Student's t-test, Kruskal-Wallis and Permutation tests and Fisher tests, as indicated.
Supplementary Material
Supplementary Material is available at HMG online.
